JonesResearch analyst Soumit Roy initiated coverage of Protara Therapeutics (TARA) with a Buy rating and $21 price target The stock is currently trading at cash value, the analyst tells investors in a research note. The firm says Protara has three diverse, late-stage clinical programs, two of which are “fairly de-risked.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Therapeutics Reports Q1 2025 Financial Results
- Protara Therapeutics: Buy Rating Affirmed Amid Promising Clinical Data and Strong Financial Position
- Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC with Strong Efficacy and Safety Profile
- Protara Therapeutics appoints Nicacio as CMO, Williams as CPO
- Protara Therapeutics reports Q1 EPS (29c), consensus (48c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue